AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21094089 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax (14/21 dosing schedule) at doses of 10, 20, 40, 80, 110, 160, 225, 315, or 440 mg/day
Number of subjects: 55
Study 21094089 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax (21/21 dosing schedule) at doses of 200, 275, 325, or 425 mg/day
Number of subjects: 55
Study 21094089 — intervention group
Group type: EXPERIMENTAL
Intervention: Navitoclax (150 mg/day lead-in dose followed by 325 mg on continuous 21/21 schedule)
Number of subjects: 55
Study 21095016 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 21095016 — intervention group
Group type: EXPERIMENTAL
Intervention: OFC
Number of subjects: 0
Study 21095016 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs (rs4938016, rs2734848, rs2734841, rs1124493, rs1076562)
Number of subjects: 0
Study 21095488 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive levetiracetam (LEV) 20 to 80 mg/kg/d for up to 48 weeks
Number of subjects: 152
Study 21095488 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive levetiracetam (LEV)
Number of subjects: 152
Study 21098399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (400 mg twice daily)
Number of subjects: 321
Study 21098436 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable everolimus drug-eluting vascular scaffold
Number of subjects: 45
Study 21098526 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-PCV7
Number of subjects: 3
Study 21098526 — intervention group
Group type: EXPERIMENTAL
Intervention: Early post-PCV7
Number of subjects: 3
Study 21098526 — intervention group
Group type: EXPERIMENTAL
Intervention: Late post-PCV7
Number of subjects: 3
Study 21098574 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 20
Study 21106443 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Number of subjects: 631
Study 21106443 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 631
Study 21106711 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 115
Study 21106711 — intervention group
Group type: EXPERIMENTAL
Intervention: ERα polymorphisms
Number of subjects: 115
Study 21106711 — intervention group
Group type: EXPERIMENTAL
Intervention: ERα PvuII T>C polymorphism
Number of subjects: 115
Study 21106722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg
Number of subjects: 75
Study 21106722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 75
Study 21106722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab with multipeptide immunizations (HLA-A*0201+ patients)
Number of subjects: 75
Study 21106722 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher changes in Th-17 inducible frequency
Number of subjects: 75
Study 21106722 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline C-reactive protein (CRP) levels
Number of subjects: 75
Study 21107682 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 5 mg/day plus vinorelbine and trastuzumab
Number of subjects: 50
Study 21107682 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 30 mg/week plus vinorelbine and trastuzumab
Number of subjects: 50
Study 21107682 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 20 mg/week plus vinorelbine and trastuzumab
Number of subjects: 50
Study 21107682 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study 21108818 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepandemic (H5N1) influenza vaccine adjuvanted with AS03A (3.75 μg haemagglutinin)
Number of subjects: 100
Study 21108818 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepandemic (H5N1) influenza vaccine adjuvanted with AS03A
Number of subjects: 100
Study 21109011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem high-dose therapy (HDT) with autologous peripheral blood stem cell (PBSC) support; Induction with anthracyclin-containing regimen followed by tandem HDT conditioned by high-dose mitoxantrone plus cytarabine for the first HDT and total-body irradiation (TBI), carmustine, etoposide, and cyclophosphamide for the second HDT
Number of subjects: 45
Study 21109011 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem high-dose therapy (HDT) with autologous peripheral blood stem cell (PBSC) support
Number of subjects: 45
Study 21109229 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapeutic keratectomy (PTK) with low-dose mitomycin C (MMC) 0.002% for 1 minute
Number of subjects: 23
Study 21109344 — intervention group
Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 955
Study 21109344 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 955
Study 21109344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 955
Study 21109690 — intervention group
Group type: EXPERIMENTAL
Intervention: Karyotyping
Number of subjects: 302
Study 21109690 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization
Number of subjects: 302
Study 21109690 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 302
Study 21110749 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0
Study 21110749 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 0
Study 21110865 — intervention group
Group type: EXPERIMENTAL
Intervention: French speaking areas
Number of subjects: 542
Study 21110865 — intervention group
Group type: COMPARATOR
Intervention: Swiss parents
Number of subjects: 542
Study 21110865 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal workload and parental education
Number of subjects: 542
Study 21110865 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional differences
Number of subjects: 542
Study 21111785 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (5.0mg, n=12)
Number of subjects: 22
Study 21111785 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (1.0mg, n=10)
Number of subjects: 22
Study 21111983 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-based performance improvement intervention
Number of subjects: 15170
Study 21115606 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' perception of COPD symptoms
Number of subjects: 2441
Study 21115606 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathlessness as a symptom
Number of subjects: 2441
Study 21115606 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily and/or weekly symptom variability
Number of subjects: 2441
Study 21115606 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with perception of variability
Number of subjects: 2441
Study 21115606 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of variability by region
Number of subjects: 2441
Study 21115606 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact on daily activities
Number of subjects: 2441
Study 21115606 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment of treatment
Number of subjects: 2441
Study 21117946 — intervention group
Group type: COMPARATOR
Intervention: Candesartan 32 mg + Hydrochlorothiazide 25 mg (Phase 1)
Number of subjects: 186
Study 21117946 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg + Hydrochlorothiazide 25 mg (Phase 2)
Number of subjects: 186
Study 21117946 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg + Hydrochlorothiazide 25 mg + Amlodipine 5 mg (optional extension)
Number of subjects: 186
Study 21118562 — intervention group
Group type: EXPERIMENTAL
Intervention: Paleolithic diet (n = 14)
Number of subjects: 29
Study 21118562 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean-like diet (n = 15)
Number of subjects: 29
Study 21118739 — intervention group
Group type: EXPERIMENTAL
Intervention: New disposable rhGH injection pen
Number of subjects: 136
Study 21123095 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-completed WIQ (Walking Impairment Questionnaire)
Number of subjects: 73
Study 21123095 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervision of self-completed WIQs
Number of subjects: 73
Study 21123095 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall WIQ score
Number of subjects: 73
Study 21123449 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment for obstructive sleep apnea (OSA) for 8 weeks
Number of subjects: 0
Study 21123592 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm technology for data collection
Number of subjects: 0
Study 21123592 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 21123825 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase-based treatment
Number of subjects: 19
Study 21124227 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART-exposed infants
Number of subjects: 1059
Study 21124227 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine-exposed infants
Number of subjects: 1059
Study 21126328 — intervention group
Group type: EXPERIMENTAL
Intervention: HRP2-based rapid diagnostic test (Paracheck)
Number of subjects: 300
Study 21126328 — intervention group
Group type: COMPARATOR
Intervention: HC microscopy
Number of subjects: 300
Study 21126328 — intervention group
Group type: COMPARATOR
Intervention: Expert microscopy
Number of subjects: 300
Study 21127362 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular syringes (RPD syringe)
Number of subjects: 437
Study 21129762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambisome plus miltefosine
Number of subjects: 135
Study 21129762 — intervention group
Group type: COMPARATOR
Intervention: Ambisome
Number of subjects: 135
Study 21129762 — intervention group
Group type: COMPARATOR
Intervention: miltefosine
Number of subjects: 135
Study 21130380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecallantide (30 mg subcutaneous)
Number of subjects: 143
Study 21130380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 21131369 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate at doses of 800 mg/day (continuous)
Number of subjects: 90
Study 21131369 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate at doses of 400 mg b.i.d.
Number of subjects: 90
Study 21131369 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate at doses of 800 mg/day (intermittent)
Number of subjects: 90
Study 21131369 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate at doses of 180-800 mg
Number of subjects: 90
Study 21131369 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate at doses ≤1000 mg/day
Number of subjects: 90
Study 21131369 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate at maximum tolerated dose (MTD) of 800 mg/day
Number of subjects: 90
Study 21131410 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Number of subjects: 0
Study 21131410 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21131552 — intervention group
Group type: EXPERIMENTAL
Intervention: ENMD-2076 at 200 mg/m(2)
Number of subjects: 67
Study 21131552 — intervention group
Group type: EXPERIMENTAL
Intervention: ENMD-2076 at 160 mg/m(2) (MTD)
Number of subjects: 67
Study 21131552 — intervention group
Group type: EXPERIMENTAL
Intervention: ENMD-2076 (various doses: 60, 80, 120, 160, 200 mg/m(2))
Number of subjects: 67
Study 21131552 — intervention group
Group type: EXPERIMENTAL
Intervention: ENMD-2076 (specifically in patients with platinum refractory/resistant ovarian cancer)
Number of subjects: 67
Study 21131590 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG from patients with acquired hemophilia
Number of subjects: 65
Study 21134243 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sotrastaurin once between days 1-3 and once between days 5-8 post-transplant
Number of subjects: 13
Study 21134243 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sotrastaurin
Number of subjects: 13
Study 21134574 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive children
Number of subjects: 364
Study 21134574 — intervention group
Group type: EXPERIMENTAL
Intervention: LTNPs
Number of subjects: 364
Study 21134978 — intervention group
Group type: EXPERIMENTAL
Intervention: NRAS mutations in patients with advanced disease
Number of subjects: 44
Study 21134978 — intervention group
Group type: COMPARATOR
Intervention: NRAS mutations in patients with indolent systemic mastocytosis
Number of subjects: 44
Study 21134978 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal mast cells with mutations
Number of subjects: 44
Study 21134978 — intervention group
Group type: EXPERIMENTAL
Intervention: KIT-D816V detection in bone marrow CD34(+) progenitors
Number of subjects: 44
Study 21134978 — intervention group
Group type: EXPERIMENTAL
Intervention: NRAS mutation presence in bone marrow CD34(+) progenitors
Number of subjects: 44
Study 21134978 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of NRAS and KIT mutations on mast cell survival
Number of subjects: 44
Study 21134985 — intervention group
Group type: EXPERIMENTAL
Intervention: PR1 and WT1 peptides in Montanide-adjuvant with GM-CSF, administered every two weeks for a total of 6 injections
Number of subjects: 8
Study 21134985 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster injection three months after the 6th vaccine dose
Number of subjects: 8
Study 21135146 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR TKI with T790M mutation
Number of subjects: 93
Study 21135146 — intervention group
Group type: COMPARATOR
Intervention: EGFR TKI without T790M mutation
Number of subjects: 93
Study 21135251 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C treatment
Number of subjects: 0
Study 21135251 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized xenograft
Number of subjects: 0
Study 21135251 — intervention group
Group type: EXPERIMENTAL
Intervention: Global genomic sequencing
Number of subjects: 0
Study 21138567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 15
Study 21138605 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran (9 g)
Number of subjects: 10
Study 21138605 — intervention group
Group type: COMPARATOR
Intervention: Low-fibre control
Number of subjects: 10
Study 21138939 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt-1 >84 ng/L
Number of subjects: 763
Study 21138939 — intervention group
Group type: EXPERIMENTAL
Intervention: PlGF >20 ng/L
Number of subjects: 763
Study 21138939 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of troponin T and sFlt-1
Number of subjects: 763
Study 21138939 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt-1 and PlGF together with hsTnT
Number of subjects: 763
Study 21138939 — intervention group
Group type: EXPERIMENTAL
Intervention: sFlt-1
Number of subjects: 763
Study 21138939 — intervention group
Group type: COMPARATOR
Intervention: hsTnT
Number of subjects: 763
Study 21139079 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) scans
Number of subjects: 1372
Study 21139079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 1372
Study 21139079 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical symptoms or blood counts
Number of subjects: 1372
Study 21139079 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan results
Number of subjects: 1372
Study 21139079 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan or ultrasound results
Number of subjects: 1372
Study 21139575 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose peginterferon α2a
Number of subjects: 831
Study 21139575 — intervention group
Group type: COMPARATOR
Intervention: No antiviral therapy
Number of subjects: 831
Study 21140148 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (dosing modified to achieve target plasma levels)
Number of subjects: 0
Study 21140148 — intervention group
Group type: COMPARATOR
Intervention: Standard imatinib dosing
Number of subjects: 0
Study 21142268 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide ER 0.8 mg
Number of subjects: 107
Study 21142268 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide ER 2 mg
Number of subjects: 107
Study 21142268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 21143432 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release methylphenidate (OROS MPH) at a mean dose of 54 mg/day (0.90 mg/kg/day)
Number of subjects: 0
Study 21143432 — intervention group
Group type: COMPARATOR
Intervention: Healthy comparators (control group)
Number of subjects: 0
Study 21144043 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenform® Matrix (bovine dermal graft)
Number of subjects: 45
Study 21144055 — intervention group
Group type: EXPERIMENTAL
Intervention: HOP'N after-school program
Number of subjects: 715
Study 21145590 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin combined with imatinib mesylate (600 mg/d) and cytarabine (200 mg/d for 7 days)
Number of subjects: 36
Study 21145590 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin at 30-45 mg/m(2)/d
Number of subjects: 36
Study 21145590 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IM with a standard '3+7' regimen
Number of subjects: 36
Study 21145590 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell transplantation (SCT)
Number of subjects: 36
Study 21145720 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 μg formoterol
Number of subjects: 37
Study 21145855 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a (180μg/week)
Number of subjects: 163
Study 21145855 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a with ribavirin
Number of subjects: 163
Study 21145855 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFN therapy (0-4 weeks)
Number of subjects: 163
Study 21145855 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFN therapy (5-19 weeks)
Number of subjects: 163
Study 21145855 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFN therapy (20-23 weeks)
Number of subjects: 163
Study 21145855 — intervention group
Group type: COMPARATOR
Intervention: PEG-IFN therapy (24 weeks)
Number of subjects: 163
Study 21145855 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥80/80 PEG-IFN adherence
Number of subjects: 163
Study 21145855 — intervention group
Group type: EXPERIMENTAL
Intervention: Missed doses during therapy
Number of subjects: 163
Study 21146669 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular systolic dysfunction (LVSD)
Number of subjects: 406
Study 21146669 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical heart failure (HF)
Number of subjects: 406
Study 21146669 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of LVSD/HF
Number of subjects: 406
Study 21146669 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic conduction abnormalities
Number of subjects: 406
Study 21146669 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval ≥240 milliseconds
Number of subjects: 406
Study 21146669 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration ≥120 milliseconds
Number of subjects: 406
Study 21146669 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of LVSD/HF
Number of subjects: 406
Study 21147030 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS) screening with an endometrial thickness cutoff of 5.15 mm
Number of subjects: 48230
Study 21147030 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS) screening with a cutoff of 5 mm or greater
Number of subjects: 48230
Study 21147030 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS) screening with a cutoff of 5 mm or greater plus endometrial abnormalities
Number of subjects: 48230
Study 21147030 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS) screening with a cutoff of 10 mm or greater
Number of subjects: 48230
Study 21147030 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS) screening with a cutoff of 5 mm in women with no symptoms of postmenopausal bleeding
Number of subjects: 48230
Study 21147030 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS) screening in a high-risk population with a cutoff of 6.75 mm
Number of subjects: 48230
Study 21148082 — intervention group
Group type: EXPERIMENTAL
Intervention: CD56(+) APL patients treated with all-trans retinoic acid and anthracycline-based regimens
Number of subjects: 651
Study 21148082 — intervention group
Group type: COMPARATOR
Intervention: CD56(-) APL patients treated with all-trans retinoic acid and anthracycline-based regimens
Number of subjects: 651
Study 21148082 — intervention group
Group type: EXPERIMENTAL
Intervention: CD56(+) APL patients
Number of subjects: 651
Study 21148334 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection followed by chemotherapy
Number of subjects: 345
Study 21148334 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 345
Study 21148530 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
Number of subjects: 135
Study 21148532 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent 2009 influenza A (H1N1) vaccine (strain A/California/7/2009H1N1)
Number of subjects: 131
Study 21148541 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Engager™ aortic valve bioprosthesis (23 mm size)
Number of subjects: 30
Study 21148613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg orally days 1-28, every 42 days (1 cycle)
Number of subjects: 77
Study 21149673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg/m2/dose
Number of subjects: 49
Study 21149673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 40 mg/m2/dose
Number of subjects: 49
Study 21149673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 55 mg/m2/dose
Number of subjects: 49
Study 21149673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 70 mg/m2/dose
Number of subjects: 49
Study 21149673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (general)
Number of subjects: 49
Study 21149673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (PK studies)
Number of subjects: 49
Study 21149673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (immunomodulatory studies)
Number of subjects: 49